Keywords: latest, jama, findings, slam, avandia, cv, safety

Latest JAMA findings slam Avandia CV safety

Article | 17 September 2007

Print This

UK drug major GlaxoSmithKline faces new health concerns over its diabetes drug Avandia (rosiglitazone) after a meta-analysis published in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in